Singer Capital Markets is acting as Rule 3 Adviser, Nominated Adviser and Broker to Quantum Pharma plc.
Yesterday, the boards of Quantum and Clinigen announced the terms of a recommended offer to be made by Clinigen to acquire the entire issued and to be issued share capital of Quantum for £150.3 million (the “Acquisition” or the “Offer”), to be effected by means of a scheme of arrangement (the “Scheme”).
The consideration payable under the Acquisition represents a premium of approximately 46.1 per cent. to Quantum’s average share price of 56.12 pence in the three months prior to the commencement of the Offer Period.
Commenting on the Acquisition Chris Rigg, CEO of Quantum, said:
“The Quantum Board believes the strategic fit of the two Groups is strong. As part of the Clinigen Group, Quantum will be able to drive faster strategic growth and gain immediate access to international markets that will complement our existing product portfolio, provide additional routes to market for our development pipeline and accelerate the Group’s strategic plan.”
Current Market Cap: £132.97m
To get more details, email email@example.com